Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50-Day Moving Average - Here's Why

Key Points

• Karyopharm Therapeutics' stock surpassed its 50-day moving average of $5.86, reaching a high of $6.68 before settling at $6.16 during recent trading.
• Wall Street analysts have mixed ratings on Karyopharm, with four analysts giving it a Buy rating and a consensus price target of $34.00, despite a recent rating downgrade from HC Wainwright.
• The company reported a quarterly EPS of ($4.32), missing estimates, while revenue was slightly above expectations at $37.93 million.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.86 and traded as high as $6.68. Karyopharm Therapeutics shares last traded at $6.16, with a volume of 51,798 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. HC Wainwright cut shares of Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 16th. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Karyopharm Therapeutics in a research note on Saturday, September 27th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.00.

Karyopharm Therapeutics Stock Performance

The firm's 50-day moving average is $5.86 and its two-hundred day moving average is $5.15. The stock has a market cap of $53.41 million, a P/E ratio of -0.42 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The business had revenue of $37.93 million during the quarter, compared to analysts' expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. acquired a new position in Karyopharm Therapeutics in the 1st quarter worth $523,000. Two Sigma Investments LP lifted its holdings in shares of Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock valued at $93,000 after purchasing an additional 51,856 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock worth $52,000 after buying an additional 45,400 shares during the period. Bridgeway Capital Management LLC bought a new position in shares of Karyopharm Therapeutics during the second quarter worth about $163,000. Finally, Bank of America Corp DE raised its position in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company's stock valued at $726,000 after buying an additional 35,626 shares during the last quarter. Institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.